Improving treatments for acute myeloid leukemia with IDH mutations
Project 1: Increasing therapeutic efficacy in isocitrate dehydrongenase (IDH)–mutant acute myeloid leukemia (AML)
This research aims to find better ways to treat acute myeloid leukemia (AML) in patients whose cancer has specific IDH gene changes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11124242 on NIH RePORTER |
What this research studies
Current treatments for acute myeloid leukemia (AML) with IDH gene mutations work for some patients, but not all, and some patients experience a return of their cancer. This project will look closely at patient samples and conduct laboratory studies to understand why some treatments are more effective than others. Researchers will also test new combinations of therapies to improve outcomes for patients with IDH-mutant AML. This includes conducting clinical trials for patients with specific genetic profiles, such as those with both FLT3 and IDH mutations.
Who could benefit from this research
Good fit: Patients with acute myeloid leukemia (AML) who have specific IDH1 or IDH2 gene mutations, particularly those who have not responded to current IDH inhibitors or have relapsed, would be ideal candidates.
Not a fit: Patients whose acute myeloid leukemia does not have IDH1 or IDH2 mutations would likely not benefit directly from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to more effective and lasting treatments for patients with IDH-mutant AML, especially those who don't respond well to current therapies or who relapse.
How similar studies have performed: Existing IDH1 and IDH2 inhibitors are already approved and have shown success in some patients with IDH-mutant AML, but this project seeks to overcome limitations like resistance.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Levine, Ross L — Sloan-Kettering Inst Can Research
- Study coordinator: Levine, Ross L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.